Based on the current meta-analysis, IL-23 inhibitors demonstrate significant efficacy in improving joint and skin symptoms, achieving minimal disease activity, and resolving enthesitis and dactylitis in patients with psoriatic arthritis. Here, IL37 is linked to psoriatic arthritis.